Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
The MEIP news page on Stock Titan provides an organized view of public announcements and regulatory disclosures related to MEI Pharma, Inc. and its transition to Lite Strategy, Inc. These items trace the company’s path from a clinical-stage oncology business with a portfolio of cancer drug candidates to an enterprise emphasizing a Litecoin-focused digital asset treasury strategy.
Earlier news releases describe MEI Pharma’s work as a pharmaceutical company with drug candidates such as voruciclib and ME-344, along with updates on cash position, research and development spending, and the evaluation of strategic alternatives. These reports document the company’s efforts to preserve cash, consider out-licensing and merger and acquisition options, and adjust its workforce and clinical programs while seeking to maximize asset value for stockholders.
More recent articles highlight a major strategic shift: the launch of a Litecoin treasury initiative, a large private placement to fund this strategy, and the acquisition of a substantial Litecoin position. The company’s news also details the appointment of digital asset advisors, board changes linked to its treasury focus, and the formal rebranding to Lite Strategy, Inc. with a new NASDAQ ticker symbol, LITS.
Investors and researchers using this page can follow how MEI Pharma’s oncology-focused narrative evolved into a digital asset treasury story, including key milestones such as the private placement, Litecoin acquisitions, and the corporate name and ticker change. For ongoing developments after the symbol transition, users should also review news associated with Lite Strategy, Inc. under its current trading symbol.
MEI Pharma (NASDAQ:MEIP) announced its corporate rebranding to Lite Strategy, Inc. and will change its ticker to LITS effective September 11, 2025. The transformation reflects the company's strategic pivot to digital asset treasury management, focusing on Litecoin (LTC) as its primary reserve asset.
The company has already secured over $100 million in LTC with guidance from Litecoin creator Charlie Lee, who serves on the board, and GSR Ventures. While embracing this new direction, Lite Strategy continues to maintain its pharmaceutical pipeline, evaluating development opportunities for voruciclib and zandelisib.
MEI Pharma (NASDAQ: MEIP) has made a groundbreaking move by acquiring 929,548 Litecoin (LTC) tokens at an average price of $107.58, establishing a treasury valued at $110.4 million. The company becomes the first U.S.-listed public company to adopt Litecoin as a primary reserve asset.
The strategic initiative, developed with crypto investment firm GSR and guided by Litecoin Creator and MEI Board member Charlie Lee, focuses on leveraging Litecoin's reliability, operational efficiency, and broad adoption. MEI plans to update its corporate identity and potentially expand into Litecoin mining while maintaining its pharmaceutical research activities, including the development of voruciclib.
MEI Pharma (NASDAQ:MEIP) has completed a significant $100 million private placement to implement a groundbreaking Litecoin Treasury Strategy. The company sold 29,239,767 shares at $3.42 per share, becoming the first publicly traded company to adopt Litecoin (LTC) as a treasury reserve asset.
In a notable development, Charlie Lee, Litecoin's founder and a lead investor in the private placement, has joined MEI's Board of Directors. Additionally, GSR, a prominent digital asset market maker, has been appointed as the treasury's Asset Manager. The private placement included participation from the Litecoin Foundation and various crypto venture capital firms including MOZAYYX, ParaFi, and Hivemind.
MEI Pharma (NASDAQ:MEIP) has announced a groundbreaking $100 million private placement to implement a unique Litecoin treasury strategy, positioning itself as the first publicly traded company on a national exchange to hold LTC as a treasury reserve asset.
The company will issue 29,239,767 shares at $3.42 per share through a PIPE transaction. Notably, Charlie Lee, Litecoin's founder, will join MEI's Board of Directors, while GSR will serve as the treasury's Asset Manager. The private placement, expected to close around July 22, 2025, includes participation from the Litecoin Foundation and prominent crypto venture firms.
MEI Pharma (MEIP) reported its Q3 FY2025 financial position with $20.5 million in cash and cash equivalents and no outstanding debt as of March 31, 2025. The company continues its previously announced strategic alternatives review from July 2024, exploring options including out-licensing opportunities and potential M&A deals. Oppenheimer & Co. serves as the exclusive financial advisor in this process. MEI is implementing cash preservation measures, including a staged reduction-in-force aligned with its evolving operational direction. The company maintains that no developments will be disclosed until the strategic review concludes or disclosure becomes legally necessary.
MEI Pharma (MEIP) has reported its financial position for Q2 FY2025, with $23.7 million in cash and cash equivalents and no outstanding debt as of December 31, 2024. The company continues its previously announced strategic alternatives review, initiated in July 2024, exploring options including out-licensing opportunities and merger and acquisition possibilities to maximize stockholder value. Oppenheimer & Co. is serving as the exclusive financial advisor in this process.
The company has implemented cash preservation measures, including a staged reduction-in-force during the first half of fiscal year 2025. MEI Pharma notes that there is no guarantee the strategic review will result in any successful transactions, and updates will only be disclosed when legally required or upon completion of the evaluation process.
MEI Pharma (Nasdaq: MEIP) reported its financial results for the quarter ending September 30, 2024. The company is actively exploring strategic alternatives to maximize shareholder value, including out-licensing and M&A opportunities, with Oppenheimer & Co. as its exclusive financial advisor. MEI Pharma began cash preservation efforts in the first quarter of fiscal year 2025, including a reduction-in-force. The company holds $26.9 million in cash, cash equivalents, and short-term investments with no outstanding debt. There is no assurance that the exploration of strategic alternatives will result in any agreements or transactions, and the company does not expect to disclose further developments unless legally required or until the evaluation is complete.
MEI Pharma (Nasdaq: MEIP) reported its fiscal year end 2024 results, confirming the continuation of its strategic alternatives evaluation. The company announced on July 22, 2024, that it had begun this process to maximize stockholder value. Oppenheimer & Co., Inc. was engaged as the exclusive financial adviser for this review. Options under consideration include out-licensing existing programs and potential mergers or acquisitions.
To preserve cash, MEI initiated a reduction-in-force on August 1, 2024, which will progress in stages. While clinical development of voruciclib has been discontinued, some non-clinical activities for other drug candidates continue. As of June 30, 2024, MEI had $38.3 million in cash, cash equivalents, and short-term investments with no outstanding debt.
MEI Pharma (Nasdaq: MEIP) has announced the engagement of Oppenheimer & Co. Inc. as its exclusive financial advisor to assist in evaluating strategic alternatives. This move is part of the company's previously announced process to review potential options, with a focus on maximizing stockholder value. MEI Pharma emphasizes that there is no guarantee that this exploration will result in any agreements or successful transactions. The company plans to maintain discretion regarding the process and will only disclose developments if required legally or deemed appropriate by the Board of Directors.
MEI Pharma (Nasdaq: MEIP) has announced a strategic review, including potential transactions or an orderly wind-down, to maximize shareholder value. The company will implement a reduction-in-force and discontinue clinical development of voruciclib to preserve cash. Key leadership changes include:
1. CEO David M. Urso and CMO Richard Ghalie stepping down on August 1, 2024
2. Board Chairperson Charles V. Baltic III resigning immediately
3. CFO Justin File appointed as Acting CEO
4. Frederick W. Driscoll appointed as new Board Chairperson
The company will explore options such as out-licensing programs and M&A opportunities. If no advantageous alternatives are found, an orderly wind-down of operations will be considered.
FAQ
What is the current stock price of Mei Pharma (MEIP)?
What is the market cap of Mei Pharma (MEIP)?
